First patient randomized in pivotal TRANSFORM study with setanaxib

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the first patient has been randomized in...

Related Keywords

Sweden ,Stockholm ,Marie Galay ,Exchange Commission ,Trial Press ,European Medicines Agency ,Nasdaq Stockholm ,Track Designation ,Nasdaq Global Select Market ,Kidney Disease ,Private Securities Litigation Reform Act ,Patient Randomized ,Calliditas Therapeutics ,